Laurus Labs Ltd vs Sanjivani Paranteral Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Laurus Labs Ltd is ₹ 1099 as of 30 Apr 15:30 . The P/E Ratio of Laurus Labs Ltd changed from 131.5 on March 2024 to 20 on March 2023 . This represents a CAGR of -31.38% over 5 yearsThe P/E Ratio of Sanjivani Paranteral Ltd changed from 28.4 on March 2024 to 0 on March 2023 . This represents a CAGR of -100.00% over 5 years The Market Cap of Laurus Labs Ltd changed from ₹ 21113 crore on March 2024 to ₹ 15782 crore on March 2023 . This represents a CAGR of -5.65% over 5 yearsThe Market Cap of Sanjivani Paranteral Ltd changed from ₹ 175.32 crore on March 2024 to ₹ 0 crore on March 2023 . This represents a CAGR of -100.00% over 5 years The revenue of Laurus Labs Ltd for the Mar '26 is ₹ 1823 crore as compare to the Dec '25 revenue of ₹ 1784 crore. This represent the growth of 2.2% The revenue of Sanjivani Paranteral Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 22.36 crore. This represent the decline of -100% The ebitda of Laurus Labs Ltd for the Mar '26 is ₹ 523.91 crore as compare to the Dec '25 ebitda of ₹ 485.97 crore. This represent the growth of 7.81% The ebitda of Sanjivani Paranteral Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 4.13 crore. This represent the decline of -100% The net profit of Laurus Labs Ltd changed from ₹ 12.21 crore to ₹ 281.91 crore over 8 quarters. This represents a CAGR of 380.50% The net profit of Sanjivani Paranteral Ltd changed from ₹ 1.71 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Laurus Labs Ltd changed from 11.22 % on March 2021 to 17.01 % on March 2025 . This represents a CAGR of 8.68% over 5 yearsThe Dividend Payout of Sanjivani Paranteral Ltd changed from 7.33 % on March 2025 to 7.33 % on March 2025 . This represents a CAGR of 0.00% over 1 years .

About Laurus Labs Ltd

Laurus Labs Limited was originally incorporated as 'Laurus Labs Private Limited' on September 19, 2005 at Hyderabad, Andhra Pradesh, India as a private limited company.
The company was subsequently converted into a public limited company and its name was changed to Laurus Labs Limited on February 12, 2007.
Subsequently the name of the company was changed to Aptuit Laurus Limited consequent to the strategic partnership entered into by the company with Aptuit Singapore on July 19, 2007.
Thereafter the company was converted into a private limited company and its name was changed to Aptuit Laurus Private Limited on July 24, 2007.
Subsequently, company was converted into a public limited company and the name of the company was changed to Laurus Labs Limited on August 16, 2016. Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company with a leadership position in generic active pharmaceutical ingredients (APIs) in selected high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology.

About Sanjivani Paranteral Ltd

Sanjivani Paranteral Limited is a WHO-GMP certified core pharmaceutical company and a pioneer in the manufacturing of injectables and oral solids with an extensive experience spanning two-and-a-half-decades.
The Company primarily focus on life-saving drugs and has exports to over 25 countries, while catering to the needs of a vast geographic area through two WHO-GMP certified manufacturing facilities in Mumbai and Dehradun. Incorporated as a Public Limited Company in October, 1994, Sanjivani Parenteral was jointly promoted by Anami H Khemka and a team of professionals in various fields of pharmaceutical industry.
The Company is involved in the manufacturing of pharmaceutical medicines.
Its products includes oral solids, small volume parenteral and sterile powder formulations. The company is setting up a plant at Taloja, Maharashtra, to manufacture high grade anti-biotics and life saving injectibles used in various infections, pre- and post-operative.

FAQs for the comparison of Laurus Labs Ltd and Sanjivani Paranteral Ltd

Which company has a larger market capitalization, Laurus Labs Ltd or Sanjivani Paranteral Ltd?

Market cap of Laurus Labs Ltd is 59,335 Cr while Market cap of Sanjivani Paranteral Ltd is 196 Cr

What are the key factors driving the stock performance of Laurus Labs Ltd and Sanjivani Paranteral Ltd?

The stock performance of Laurus Labs Ltd and Sanjivani Paranteral Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Laurus Labs Ltd and Sanjivani Paranteral Ltd?

As of May 4, 2026, the Laurus Labs Ltd stock price is INR ₹1099.1. On the other hand, Sanjivani Paranteral Ltd stock price is INR ₹160.0.

How do dividend payouts of Laurus Labs Ltd and Sanjivani Paranteral Ltd compare?

To compare the dividend payouts of Laurus Labs Ltd and Sanjivani Paranteral Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.